Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma

BACKGROUND: Homologous Recombination Deficiency (HRD) is a predictive biomarker for ovarian cancer treated with PARP inhibitors or for breast cancer treated with first-line platinum-based chemotherapy. However, limited research is documented on platinum-based treatment prediction with HRD as a bioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Zheng, Shao, Di, Cai, Yuhang, Bi, Rui, Ju, Xingzhu, Chen, Dongju, Song, Chengcheng, Chen, Xiaojun, Li, Jin, An, Na, Li, Yunjin, Zhou, Qing, Xiu, Zhihui, Zhu, Shida, Wu, Xiaohua, Wen, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015784/
https://www.ncbi.nlm.nih.gov/pubmed/36922847
http://dx.doi.org/10.1186/s13048-023-01129-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015784/
https://www.ncbi.nlm.nih.gov/pubmed/36922847
http://dx.doi.org/10.1186/s13048-023-01129-x

Ejemplares similares